Multiple sclerosis and COVID-19 registry

Multiple sclerosis and COVID-19 registry

CMSC PR, Partners

Dear Colleagues and Clients: We know you are interested in what happens to people with MS and related diseases who develop COVID-19. PLEASE STAY TUNED!

We are working hard to set up an Online Registry that will rapidly report back information on outcomes and any possible effects of the various disease modifying therapies! We hope to have it up within a week.

Please visit www.narcrms.org for more details.

Elizabeth Porco

CMSC Press Release – Kathleen Costello, CRNP, MSCN Appointed Interim CEO of the CMSC

Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions

INforMS, Partners

Is it MS or Something Else? updated guide is published to expedite and uncover the answer

In memoriam: Barry GW Arnason, MD, FAAN

Positive Phase III results for Genentech’s Ocrevus (ocrelizumab)

INforMS, Partners

Abstracts for CMSC 2023 Annual Meeting reflect multidisciplinary multiple sclerosis research

CMSC 2023 Annual Meeting program offers cutting-edge science & clinical skill updates

NeurologyLive® and CMSC announce Giants of Multiple Sclerosis® 2023 class of inductees

CMSC PR, Partners

CMSC announces new initiatives to address disparities and inequality in multiple sclerosis care

CMSC 2023 Annual Meeting offers latest updates in multiple sclerosis diagnosis, treatment & research

Multiple sclerosis discovery could end disease’s chronic inflammation

Congratulations to Dr. Carrie Hersh for her recent publication on DMTs

The launch of the ROADMAP tool on Rare Disease Day 2023

MS Community, Partners

Meghan Beier recently joined the Rowan Center for Behavioral Health

Helius launches UpScript telehealth e-commerce site

INforMS, Partners

A new patient assistance offering from Janssen

In memoriam Dr. Jack S. Burks

In memory of Dr. George Kraft

Genentech to present new Ocrevus (ocrelizumab) data in multiple sclerosis & NMOSD research at ECTRIMS

INforMS, Partners

US FDA – Ocrevus prescribing information to include warnings for Colitis and PML

INforMS, Partners

Janssen Pharmaceuticals U.S. transparency report

INforMS, Partners

In memoriam Peter Wade, MD

Genentech premiers #MSVisibility 2022

INforMS, Partners

Sanofi’s 2022 annual pricing principles report

INforMS, Partners

MR epectroscopic imaging may help better diagnose, treat multiple sclerosis

Ublituximab, potential relapsing multiple sclerosis therapy, up for FDA approval

INforMS, Partners

NeurologyLive® announces the inaugural Giants of Multiple Sclerosis™ Program

CMSC PR, Partners

The Brain Under Siege by Dr. Howard Weiner

MS Community, Partners

Introducing Atara Biotherapeutics: the role of EBV in multiple sclerosis and the Phase II EMBOLD study

INforMS, Partners

MRI in Multiple Sclerosis Guidelines Update: North America, Europe align on new recommendations

Congratulations to Dr. Robert Lisak: recipient of ANA’s Distinguished Neurology Teacher Award

MS Community, Partners

Study on cognitive processing speed changes in RMS subjects treated with Ozanimod

INforMS, Partners

New data for Ocrevus disease progression (ocrelizumab) reinforce significant slowing

INforMS, Partners

New Genentech data at 2021 AAN highlight impact & breadth of neuroscience portfolio

INforMS, Partners

Janssen announces U.S. FDA approval of PONVORY™ (ponesimod)

INforMS, Partners

NeurologyLive® & the CMSC launches MS Cure Connections® Video Series

CMSC PR, Partners

FDA approval of intramuscular Plegridy (Peginterferon beta-1a)

INforMS, Partners

NeurologyLive® and CMSC partner to present two expert-driven webcast programs

Genentech’s enspryng for Neuromyelitis Optica Spectrum Disorder

INforMS, Partners

Mylan brings critical access to the multiple sclerosis community

INforMS, MS Community, Partners

WHO and AMA statement

Advocacy, CMSC PR, MS Community, Partners

A letter from Lemtrada regarding its home phlebotomy partner, EMSI

INforMS, Partners

A position statement in 2020: a year of turmoil

Advocacy, CMSC PR

In memoriam Susan E. Bennett, PT, DPT, EdD, NCS, MSCS

Multiple sclerosis patients can benefit from expanded services from MSAA

ZEPOSIA launch press release

Rebif® U.S. label includes pregnancy outcomes & lactation information

INforMS, Partners

New 6-year data for Genentech’s Ocrevus (ocrelizumab) findings

In memoriam: Elaine Whitaker

Coronavirus and multiple sclerosis reporting database announced by CMSC & NMSS

Coronavirus and multiple sclerosis reporting database

CMSC PR, Partners

CMSC Annual Meeting, May 27-30, 2020 in Orlando, FL announces cancellation

FDA approves Zeposia (Ozanimod), oral therapy for all with relapsing multiple sclerosis

INforMS, Partners

CMSC update on COVID-19: NMSS National Medical Advisory Committee recommendations

CMSC PR, Partners

CMSC update on the Annual Meeting and COVID-19

Please read: Coronavirus and multiple sclerosis statement

CMSC announces four winners of Pilot Research Awards for 2019

Results for Genentech’s Satralizumab in Neuromyelitis Optica Spectrum

INforMS, Partners

NeurologyLive™ adds CMSC to its Strategic Alliance Partnership program

INforMS, Partners

In Memoriam: Alan Mandel

EMD Serono initiates pivotal Phase III program for investigational Evobrutinib in RMS

INforMS, Partners

Genentech presents new six-year Ocrevus (Ocrelizumab) data

INforMS, Partners

Genentech’s Satralizumab significantly reduced relapse risk

INforMS, Partners

Janet Brown obituary

Genentech presents new Ocrevus (Ocrelizumab) biomarker data

INforMS, Partners

Press release – Genentech to present piviotal data at ECTRIMS

INforMS, Partners

Rutgers Health leading program to support multiple sclerosis children

INforMS, Partners

Dr. Anne Cross discusses strides In multiple sclerosis research, recent award

INforMS, Partners

EMD Serono’s embracing carers launches ‘Time Counts’ to raise 1M minutes of support

INforMS, Partners

CMSC opens weeklong mental health program to help mentor and train multiple sclerosis specialists

CMSC PR, Partners

Alexion’s Soliris gets new, and lucrative, rare disease indication

INforMS, Partners

CMSC, multiple sclerosis non-profits and Polar Products recognizes over twenty years of progress

CMSC PR, Partners

June Halper outlines the biggest management challenges in multiple sclerosis

In memoriam: Dr. Conomy, a founder and former Executive Director of the CMSC

Lenox Hill Hospital multiple sclerosis support group

Genentech presenting new Ocrevus (Ocrelizumab) data at AAN Meeting

INforMS, Partners

MSAA recognizes ten years of artwork from individuals with multiple sclerosis

INforMS, MS Community, Partners

OHSU doctors part of ‘breakthrough’ research on treating multiple sclerosis

INforMS, Partners

Anne Cross, neurologist with pioneering work into B-cells/multiple sclerosis, awarded John Dystel Prize

INforMS, Partners

Novartis gets FDA approval for Mayzent (Siponimod), the first oral drug to treat SPMS

INforMS, Partners

Novartis receives FDA approval for MAYZENT (Siponimod)

INforMS, Partners

In memoriam of Dr. Lael Stone

TG Therapeutics, Inc. announces final phase 2 multiple sclerosis data presentation at ECTRIMS

INforMS, Partners

Novartis announces FDA filing acceptance of Siponimod (BAF312)

INforMS, Partners

New efficacy and safety data on multiple sclerosis portfolio to be presented

INforMS, Partners

Press release – Ocrevus data show early initiation reduces progression

INforMS, Partners

Our condolences to the family of Nicola “Nicki” Ward-Abel, RGN, BSc (Hons), MSCN

Novartis announces PARADIGMS study demonstrating benefit of Gilenya®

INforMS, Partners

Call for test sites: using patient-reported outcomes to drive multiple sclerosis care

Genentech announces new Ocrevus (Ocrelizumab) data for PPMS

INforMS, Partners

TREAT-MS

CMSC PR, Partners

New Ocrevus (Ocrelizumab) data demonstrate reductions In activity & progression In RMS

INforMS, Partners

Imagerywork

Phase III data in the lancet show Novartis outcomes in secondary progressive multiple sclerosis

INforMS, Partners

Abbvie and Biogen pull multiple sclerosis drug Zinbryta following urgent EMA safety review

INforMS, Partners

CVS/Aetna combo a formidable pharma rival when it comes to access

INforMS, Partners

Press Release – CMSC receives Interprofessional Continuing Education Joint Accreditation

National Multiple Sclerosis Society endorses multiple sclerosis “NARCRMS” data registry

CMSC PR, INforMS, Partners

Mayo Clinic develops test to distinguish other demyelinating diseases from multiple sclerosis

INforMS, Partners

Patients tell their stories in Consortium of Multiple Sclerosis Centers’ online videos

CMSC PR, MS Community

International Journal of Multiple Sclerosis Care wins 2017 APEX Award

CMSC PR, Partners

Consortium announces new multiple sclerosis Physician Assistant special interest group

OMRF multiple sclerosis center wins top multiple sclerosis research award

INforMS, Partners

Research sheds light on who’s multiple sclerosis could worsen

INforMS, MS Community, Partners

CMSC revises recommendations for Gadolinium use in MRIs

CMSC 2017 Annual Meeting – Ocrevus, progressive multiple sclerosis and other research highlights

Acne therapy reduces rate of multiple sclerosis progression, Canadian study reports

CMSC 2017 Annual Meeting – caregivers of multiple sclerosis patients say the disease exhausts physically & emotionally

Bayer receives FDA approval of myBETAapp™ and BETACONNECT Navigator™

MS Community, Partners

CMSC 2017 Annual Meeting – Ocrevus lowers multiple sclerosis relapse rates even further in extension study

CMSC 2017 Annual Meeting – physical activity halts depression in young multiple sclerosis patients, Canadian study shows

CMSC 2017 Annual Meeting – Celgene’s investigational therapy Ozanimod safe, effective in treating RMS

CMSC PR, Partners

CMSC 2017 Annual Meeting – Rituxan-treated multiple sclerosis patients three times more likely to have improved brain scans

CMSC PR, Partners

CMSC 2017 Annual Meeting – Cladribine reduced annual multiple sclerosis relapse rate by 55% to 57%, trials show

CMSC 2017 Annual Meeting – review suggests certain multiple sclerosis patient groups may discontinue DMTs

CMSC PR, Partners

CMSC 2017 Annual Meeting – Tysabri improves mental outlook for patients with secondary progressive MS

CMSC PR, Partners

CMSC 2017 Annual Meeting – feeling of social stigma makes depression in multiple sclerosis more likely, study reports

CMSC 2017 Annual Meeting – multiple sclerosis patients should contribute to outcome measure development, study argues

CMSC PR, Partners

CMSC 2017 Annual Meeting – multiple sclerosis mobile apps link clinicians and patients, improving disease management

CMSC 2017 Annual Meeting – relapse after first Lemtrada course no indication of poor long-term outcome

CMSC 2017 Annual Meeting – single session of ball-throwing exercise improves balance control in multiple sclerosis

CMSC PR, Partners

CMSC 2017 Annual Meeting – Genentech starts site to connect multiple sclerosis patients and caregivers with resources

CMSC PR, Partners

CMSC 2017 Annual Meeting – all about teamwork in multiple sclerosis

CMSC PR, Partners

The hidden costs of multiple sclerosis

INforMS, Partners

David Sackett trial of the year awarded to the Oratorio Study

MS Community, Partners

CMSC 2017 Annual Meeting – experts to focus on multiple sclerosis patient care at CMSC Annual Meeting in New Orleans

CMSC PR, Partners

Biogen Idec to present new two-year data from the PLEGRIDY phase 3 advance study

INforMS, Partners

In memoriam – Dr. William Sheremata

Stress and MS: Webinar from IOMSN helps manage daily stress

LiveWiseMS – a new online resource for people with multiple sclerosis

Ari Waisman receives most prestigious European prize for multiple sclerosis research

Consortium of Multiple Sclerosis Centers calls for abstracts for CMSC 2017 Annual Meeting

United Spinal Association offering range of materials at exhibit booth at CMSC 2016 Annual Meeting

CMSC PR, Partners

In memoriam – Dr. Omar Khan

Multiple sclerosis rehabilitation specialist, Susan Bennett, receives CMSC Lifetime Achievement Award

CMSC PR, Partners

ICER draft report evaluating therapies for RRMS now open for public comment

INforMS, Partners

CMSC 2016 Annual Meeting – Clay Walker’s concert at the CMSC 30th anniversary celebration

CMSC PR, Partners

How does menopause affect women with multiple sclerosis?

INforMS, MS Community, Partners

CMSC 2016 Annual Meeting – Multiple Sclerosis News Today’s exclusive interview with Mark Freedman

CMSC PR, Partners

CMSC 2016 Annual Meeting – Multiple Sclerosis News Today’s exclusive interview with Summer Kernan

CMSC PR, Partners

Nine CMSC 2016 Annual Meeting exclusive interviews you can’t miss

CMSC PR, Partners

CMSC 2016 Annual Meeting – metabolism in multiple sclerosis and the role of mitochondrial dysfunction

CMSC 2016 Annual Meeting – tai chi shown to improve balance and strength in multiple sclerosis patients

CMSC 2016 Annual Meeting – multiple sclerosis rehab clinical practice guideline help patients achieve excellent results

CMSC 2016 Annual Meeting – multiple sclerosis patients’ speech limitations and difficulty in swallowing may be measured

CMSC 2016 Annual Meeting – aging multiple sclerosis patients experience greater physical dysfunction

CMSC 2016 Annual Meeting – physical training with assistive devices improves mobility for multiple sclerosis patients

CMSC 2016 Annual Meeting – Fingolimod (Gilenya) offers consistent health benefits in RRMS patients

CMSC PR, Partners

CMSC 2016 Annual Meeting – multiple sclerosis mice show reduced disease severity after treatment with vegetable compound

CMSC 2016 Annual Meeting – multiple sclerosis patients, physical therapists have distinct decision-making processes

CMSC PR, Partners

CMSC 2016 Annual Meeting – home DVD-guided exercise may help older multiple sclerosis patients

CMSC 2016 Annual Meeting – multiple sclerosis duration and disability level variously impacts arm function

CMSC PR, Partners

CMSC 2016 Annual Meeting – multiple sclerosis and yoga: author and instructor says ancient discipline can help patients

CMSC PR, Partners

CMSC 2016 Annual Meeting – Ocrevus (Ocrelizumab) in PPMS prevented disability progression

CMSC PR, Partners

CMSC 2016 Annual Meeting – Genentech’s Ocrelizumab a promising therapy for primary progressive multiple sclerosis

CMSC 2016 Annual Meeting – RRMS patients’ five-year clinical outcome improved – find out how

CMSC 2016 Annual Meeting – strive study confirms Tysabri safety in early relapsing-remitting multiple sclerosis

CMSC 2016 Annual Meeting – RRMS patients on Alemtuzumab (Lemtrada) show slowed disability progression

CMSC 2016 Annual Meeting – delayed-release Dimethyl Fumarate benefits newly diagnosed multiple sclerosis patients

CMSC 2016 Annual Meeting – stem cell transplants – an exciting multiple sclerosis therapy development

CMSC 2016 Annual Meeting – multiple sclerosis patients of African descent may fare better on Alemtuzumab (Lemtrada)

CMSC 2016 Annual Meeting – multiple sclerosis care should include fatigue, sleep quality and inattentiveness assessment

CMSC 2016 Annual Meeting – multiple sclerosis research highlights what improves with clinical care

CMSC 2016 Annual Meeting– assessing/treating psychiatric disorders in multiple sclerosis patients may improve prognosis

CMSC 2016 Annual Meeting – hispanic multiple sclerosis patients featured in film to promote health, self-care

CMSC 2016 Annual Meeting – fatigue in multiple sclerosis might be handled with interactive self-management resource

CMSC 2016 Annual Meeting – multiple sclerosis patients at higher risk for loneliness, study shows

CMSC 2016 Annual Meeting – exclusive interview with Dr. Rosalind Kalb on multiple sclerosis care and family involvement

CMSC 2016 Annual Meeting – study aims to improve multiple sclerosis care by considering patients’ perspectives

CMSC PR, Uncategorized

CMSC 2016 Annual Meeting – women with multiple sclerosis have significant depression, fatigue, decline in cognitive function

CMSC 2016 Annual Meeting – new screening tool for swallowing difficulties in multiple sclerosis evaluated

CMSC 2016 Annual Meeting – sexual dysfunction in hispanic multiple sclerosis patients exists with other issues, study

CMSC 2016 Annual Meeting – medical affairs vice president at EMD Serono discusses multiple sclerosis drug rebif, Multiple Sclerosis LifeLines

CMSC PR, Partners

CMSC 2016 Annual Meeting – lifestyle factors and unconventional medicine in multiple sclerosis care

CMSC 2016 Annual Meeting – Multiple Sclerosis News Today’s exclusive interview with June Halper

CMSC 2016 Annual Meeting – multiple sclerosis expert Fred Lublin discusses relevance of multiple sclerosis relapses

CMSC 2016 Annual Meeting – Patricia Coyle, a multiple sclerosis expert, talks about Vitamin D, fatigue & other issues

CMSC 2016 Annual Meeting – Multiple Sclerosis News Today to provide on-site coverage of annual meeting

4 reasons for multiple sclerosis patients to keep track of the CMSC 2016 Annual Meeting

CMSC congratulates Kessler Foundation for this prestigious recognition

CMSC PR, Partners

CMSC 2016 Annual Meeting final program

Dr. Ellen Mowry, in Interview, talks of clinical studies for Vitamin D & multiple sclerosis

CMSC PR, Partners

Scientific abstracts for the CMSC 2016 Annual Meeting

High glutamate levels in brain seen to drive multiple sclerosis progression

CMSC PR, Partners

CMSC 2016 Annual Meeting agenda

CMSC 2016 Annual Meeting goals and highlights

CMSC 2016 Annual Meeting – multiple sclerosis experts agree on benefits of Vitamin D supplements

CMSC 2016 Annual Meeting – Dr. Fred Lublin opening lecture on multiple sclerosis relapses and impact on patient outcome

CMSC 2016 Annual Meeting – an interview with June Halper, the Consortium’s CEO and a multiple sclerosis Nurse Practitioner

New data from three Phase III studies of the medicine OCREVUS™ (ocrelizumab)

In memoriam – Toni Chiara

In memoriam – Dr. Rossman

Francois Bethoux, MD, named medical director of the Arts & Medicine Institute

National Multiple Sclerosis Society honors physician

MedDay misses endpoint in phase III multiple sclerosis vision loss trial

INforMS, Partners

John F. Kurtzke, MD, remembered

CMSC issues position statement on Aaccess to medications to treat symptoms of multiple sclerosis

Biogen reports top-line results from phase 3 study evaluating Natalizumab in SPMS

INforMS, Partners

EMD Serono announces publication of PRISMS-15 year follow-up study using Rebif in RRMS

INforMS, Partners

Treatment effects maintained over 5 years in patients with RRMS who received Lemtrada

INforMS, Partners

Genentech’s Ocrelizumab show positive pivotal study results in both RRMS and PPMS

INforMS, Partners

EMD Serono announces recipients of the third annual €1 million grant for multiple sclerosis innovation

INforMS, Partners

New analysis suggests Aubagio slows brain atrophy in people with Relapsing MS

INforMS, Partners

Data show effects of TECFIDERA in newly-diagnosed and early disease course multiple sclerosis patients

INforMS, Partners

Genzyme introduces “vs.MS”, a global initiative

INforMS, MS Community, Partners

Genentech’s Ocrelizumab to show efficacy in people with PPMS in large phase III study

INforMS, Partners

Bayer receives FDA approval for BETACONNECT

INforMS, Partners

Novartis acquires all remaining rights to GSK Ofatumumab to develop treatments for multiple sclerosis

INforMS, Partners

EMD Serono and Opexa amend agreement to support ongoing development of Tcelna for multiple sclerosis

INforMS, Partners

Multiple Sclerosis Coalition applauds passage of 21st Century Cures Act

MS Community, Partners

Genentech’s Ocrelizumab reduced both relapses and disability progression versus Rebif

INforMS, Partners

Multiple Sclerosis Coalition announces new board President

CMSC PR, Partners

Sandoz announces US launch of Glatopa, the first generic competitor to Copaxone 20mg

INforMS, Partners

Novartis statement on reported case of PML

INforMS, Partners

FDA accepts biologics license application for ZINBRYTA for treatment of multiple sclerosis

INforMS, Partners

Mallinckrodt research fellowship award program announcement

INforMS, Partners

FDA accepts filing of BETACONNECT for RRMS patients taking BETASERON

INforMS, Partners

International survey identifies opportunities for improving multiple sclerosis treatment satisfaction

INforMS, MS Community, Partners

TECFIDERA Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients

INforMS, Partners

EMA validates marketing authorization application for ZINBRYTA for treatment of multiple sclerosis

INforMS, Partners

Teva Neuroscience & Access Health team up for special multiple sclerosis awareness show: thursday, 3/5

INforMS, MS Community, Partners

Acorda announces data from first clinical trial of remyelinating antibody in multiple sclerosis

INforMS, Partners

The latest in multiple sclerosis care & research to be presented at educational conference for healthcare professionals

First multiple sclerosis patients in the U.S. receive Genzyme’s Lemtrada following FDA approval

INforMS, Partners

CMSC announces a virtual support group for multiple sclerosis patients

Genzyme’s Lemtrada approved by the FDA

INforMS, Partners

Genzyme announces enrollment of first patient in phase II Vatelizumab trial in RRMS

INforMS, MS Community, Partners

Study on abnormal MRIs and the risk of developing multiple sclerosis featured in the IJMSC

Optimizing multiple sclerosis management – new CME/CE courses for healthcare professionals

CMSC PR, Partners

Results from two phase III studies added to U.S. label of Genzyme’s Aubagio

INforMS, Partners

Employment in Multiple Sclerosis (MS) study

MS Community, Partners

Novartis teams up with multiple sclerosis advocate David Osmond to launch Our Voice in Song

MS Community, Partners

At four years, treatment effect maintained in patients who received Lemtrada in studies

INforMS, Partners

New international survey finds multiple sclerosis patients and neurologists view communication positively

INforMS, MS Community, Partners

CMSC announces new President & board members

IJMSC features article on the Multiple Sclerosis Self-Management Scale

AIMS presents the latest on multiple sclerosis treatments

CMSC PR, Partners

Biogen Idec’s PLEGRIDY approved in the US for the treatment of multiple sclerosis

INforMS, Partners

Psychology continuing education credit offered at multiple sclerosis conference

Record attendance at the cooperative meeting of CMSC & ACTRIMS

PLEGRIDY (Peginterferon beta-1a) approved in the EU for the treatment of multiple sclerosis

INforMS, Partners

Teva files citizen petition with the US FDA regarding the complexity of COPAXONE

INforMS, Partners

Genzyme’s Lemtrada approved in Argentina for treatment of multiple sclerosis

INforMS, Partners

Biogen Idec and AbbVie Announce Results from Phase 3 Study Investigating Daclizumab

INforMS, Partners

Official reports from the 2014 cooperative meeting of CMSC & ACTRIMS – 5/31/2014

Workforce of the Future spotlighted at multiple sclerosis conference

Genzyme’s Lemtrada resubmission accepted for review by FDA

INforMS, Partners

Data from Biogen Idec’s portfolio of multiple sclerosis therapies and pipeline featured at congresses

INforMS, Partners

Official reports from the 2014 cooperative meeting of CMSC & ACTRIMS – 5/30/2014

Official reports from the 2014 cooperative meeting of CMSC & ACTRIMS – 5/29/2014

Biogen Idec announces official partnership with Sailing Sclerosis’ “Oceans of Hope”

INforMS, Partners

EMD Serono data at CMSC & ACTRIMS Annual Meeting reinforces proven efficacy of rebif

CMSC PR, Partners

Media alert — grow your multiple sclerosis knowledge

Acorda Therapeutics to showcase online multiple sclerosis resources at 2014 CMSC/ACTRIMS meeting

CMSC PR, Partners

Genzyme recognizes sixth annual World MS Day

INforMS, MS Community, Partners

CHMP adopts positive opinion for PLEGRIDY as a treatment for multiple sclerosis in the EU

INforMS, Partners

Teva announces COPAXONE recognized as “Brand of the Year” by Pharm Exec Magazine

INforMS, Partners

Leading multiple sclerosis conference offers continuing education credit for pharmacists

New TYSABRI analysis shows improved walking speed in significant number of multiple sclerosis patients

INforMS, Partners

New data reinforce efficacy of TECFIDERA in multiple sclerosis patients with high disease activity

INforMS, Partners

A farewell tribute to Mike Robinson – President, National Multiple Sclerosis Society of Zimbabwe

Slowing of brain atrophy sustained at three years in patients treated with Lemtrada

INforMS, Partners

Genzyme announces multi-year multiple sclerosis research collaboration with academic medical center

INforMS, Partners

Top multiple sclerosis experts headline conference focused on comprehensive approach to care

Dr. T.J. ‘Jock’ Murray is a 2014 inductee to the Canadian Medical Hall of Fame

Teva announces supreme court denial of request for interim relief to stay

INforMS, Partners

Biogen Idec to present new clinical data at AAN Annual Meeting

INforMS, Partners

New continuing education program helps distinguish between primary care needs & multiple sclerosis symptoms

CMSC PR, Partners

CMSC launches new mental health special interest group (MS-MHP)

Comments are closed.